KYTX vs LXEO

Kyverna Therapeutics, Inc. vs Lexeo Therapeutics, Inc. — Valuation Comparison 2026

KYTX

Biological Products, (No Diagnostic Substances)
Kyverna Therapeutics, Inc.
Quality
4.2
out of 10
Value Trap
18
SAFE
Price
$8.52
Last close
Models
7/13
Active
VS

LXEO

Biological Products, (No Diagnostic Substances)
Lexeo Therapeutics, Inc.
Quality
4.5
out of 10
Value Trap
12
SAFE
Price
$5.14
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType KYTX Fair ValueKYTX Upside LXEO Fair ValueLXEO Upside
Bayesian DCF Intrinsic $2.40 -71.8% $1.82 -64.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $2.70 -68.3% $0.15 -97.3%
Dynamic NAV Asset-Based $3.58 -57.9% $2.81 -45.3%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for KYTX vs LXEO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

KYTX vs LXEO — Which Stock Is More Undervalued?

LXEO scores higher with a 4.5/10 quality rating vs KYTX's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Kyverna Therapeutics, Inc. (KYTX) and Lexeo Therapeutics, Inc. (LXEO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

KYTX currently trades at $8.52 with a QOC of 4.2/10, while LXEO trades at $5.14 with a QOC of 4.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).